Pfizer Inc. (NYSE:PFE) Shares Sold by Stock Yards Bank & Trust Co.

Stock Yards Bank & Trust Co. decreased its holdings in shares of Pfizer Inc. (NYSE:PFE) by 10.6% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 102,381 shares of the biopharmaceutical company’s stock after selling 12,171 shares during the quarter. Stock Yards Bank & Trust Co.’s holdings in Pfizer were worth $2,716,000 at the end of the most recent quarter.

Several other institutional investors have also recently added to or reduced their stakes in PFE. Retirement Wealth Solutions LLC acquired a new position in shares of Pfizer in the fourth quarter valued at approximately $26,000. Gladius Capital Management LP grew its holdings in Pfizer by 102.8% during the third quarter. Gladius Capital Management LP now owns 1,043 shares of the biopharmaceutical company’s stock worth $30,000 after acquiring an additional 38,015 shares during the period. Quarry LP acquired a new position in Pfizer during the second quarter worth $31,000. Teachers Insurance & Annuity Association of America acquired a new position in Pfizer during the third quarter worth $35,000. Finally, Joseph Group Capital Management grew its holdings in Pfizer by 168.3% during the third quarter. Joseph Group Capital Management now owns 1,229 shares of the biopharmaceutical company’s stock worth $36,000 after acquiring an additional 771 shares during the period. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Wall Street Analysts Forecast Growth

PFE has been the topic of several recent research reports. Citigroup reduced their price objective on Pfizer from $30.00 to $29.00 and set a “neutral” rating on the stock in a research report on Tuesday, January 28th. Sanford C. Bernstein initiated coverage on Pfizer in a report on Thursday, October 17th. They set a “market perform” rating and a $32.00 target price on the stock. Truist Financial lowered their price target on Pfizer from $36.00 to $32.00 and set a “buy” rating for the company in a report on Wednesday, December 18th. Cantor Fitzgerald restated an “overweight” rating and set a $45.00 price objective on shares of Pfizer in a research report on Wednesday, October 23rd. Finally, Evercore ISI upgraded Pfizer to a “strong-buy” rating in a research report on Wednesday, October 30th. One investment analyst has rated the stock with a sell rating, eight have issued a hold rating, six have issued a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $31.92.

Pfizer Stock Down 1.5 %

Shares of PFE opened at $26.51 on Monday. Pfizer Inc. has a one year low of $24.48 and a one year high of $31.54. The company has a market cap of $150.20 billion, a P/E ratio of 35.82, a P/E/G ratio of 0.66 and a beta of 0.64. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.73. The firm has a 50 day simple moving average of $26.27 and a two-hundred day simple moving average of $27.86.

Pfizer Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, March 7th. Stockholders of record on Friday, January 24th will be issued a dividend of $0.43 per share. The ex-dividend date is Friday, January 24th. This is an increase from Pfizer’s previous quarterly dividend of $0.42. This represents a $1.72 annualized dividend and a dividend yield of 6.49%. Pfizer’s dividend payout ratio is 232.44%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.